SCHEMBL218369

SCHEMBL218369

CCC(CC)Nc1nc(N)ncc1C#N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ PIK3CD O00329 2/20 0.40
▸ PIK3R1 P27986 1/20 0.40
▸ CSNK1A1 P48729 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ CHUK O15111 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ EGFR P00533 2/20 0.35
▸ PRKDC P78527 2/20 0.35
▸ NUDT1 P36639 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.35
▸ CRHR1 P34998 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL250961 0.87 PIK3CD (0.41) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL251804 0.87 PIK3CD (0.41) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL217591 0.87 PIK3CD (0.41) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL21389720 0.84 PIK3CD (0.40) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL179466 0.83 PIK3CD (0.38) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL179438 0.83 PIK3CD (0.38) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL179430 0.83 PIK3CD (0.38) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL18708695 0.83 PIK3CD (0.38) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL15354452 0.83 LRRK2 (0.47) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1
SCHEMBL12692538 0.82 PIK3CD (0.37) ADORA2AADORA1PIK3CDPIK3R1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522146-B2 Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof INTELLIKINE LLC (US) 2016-12-20 — — US disclosed
US-20160016957-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION INFINITY PHARMACEUTICALS, INC. 2016-01-21 — — US disclosed
US-9216982-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2015-12-22 — — US disclosed
US-20140377258-A1 Treatment Of Cancers Using PI3 Kinase Isoform Modulators INFINITY PHARMACEUTICALS, INC. (US) 2014-12-25 — — US disclosed
US-20140341894-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2014-11-20 — — US disclosed
US-8569323-B2 Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof INTELLIKINE, LLC (US) 2013-10-29 — — US disclosed
US-20130053362-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLKINE, LLC (US) 2013-02-28 — — US disclosed
US-20120245169-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2012-09-27 — — US disclosed
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2012-06-14 — — US disclosed
US-8193182-B2 Substituted isoquinolin-1(2H)-ones, and methods of use thereof INTELLIKINE, INC. (US) 2012-06-05 — — US disclosed
US-20120059000-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION INFINITY PHARMACEUTICALS, INC. 2012-03-08 — — US disclosed
US-20090312319-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE 2009-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140377258-A1 Treatment Of Cancers Using PI3 Kinase Isoform Modulators PIK3CA, MCL1, PIK3CB ADORA2A 2591/4885ADORA1 3908/4885PIK3CD 4/4885
US-20130053362-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AKT3, PIK3CA, AKT1 ADORA2A 1341/4885ADORA1 2275/4885PIK3CD 5/4885
US-20090312319-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CB ADORA2A 1048/4885ADORA1 2085/4885PIK3CD 4/4885
US-20120059000-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION MAP3K13, AKT3, PIK3CA ADORA2A 1787/4885ADORA1 2434/4885PIK3CD 18/4885
US-20120245169-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CB ADORA2A 1048/4885ADORA1 2085/4885PIK3CD 4/4885
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A ADORA2A 1252/4885ADORA1 1782/4885PIK3CD 7/4885
US-20140341894-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A ADORA2A 1252/4885ADORA1 1782/4885PIK3CD 7/4885
US-20160016957-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION MAP3K13, AKT3, PIK3CA ADORA2A 1787/4885ADORA1 2434/4885PIK3CD 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback